| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445376 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6Â mg/kg. The recommended phase II dose was 0.45-0.6Â mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Silke Gillessen, Ulrike S. Gnad-Vogt, Elisa Gallerani, Joachim Beck, Cristiana Sessa, Aurelius Omlin, Maria R. Mattiacci, Bernd Liedert, Daniel Kramer, Julien Laurent, Daniel E. Speiser, Roger Stupp,